Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Treatment Trends in Prostate Cancer at MD Anderson Versus Nationwide
At-Home Urine Collection as a Diagnostic Tool for Prostate Cancer
MRI-Guided Ultrasound Technique for Localized Prostate Cancer
FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
Hemigland Cryoablation for Localized Prostate Cancer: Outcomes at 5 Years
Exercise and Treatment-Related Toxicity to Be Studied in Men With Advanced Prostate Cancer
Is There an Association Between Antidiabetic Medication and Prostate Cancer?
Update on Survival Outcomes With Long-Term Docetaxel in Metastatic Prostate Cancer
Cabazitaxel or Androgen Receptor–Targeted Therapies for Metastatic Prostate Cancer
Noninvasive Blood Test May Improve Accuracy in Detecting Prostate Cancer
In-House Specialty Pharmacy and Cost of Therapies for Prostate Cancer
ESMO 2019: CHEIRON Update on Enzalutamide Plus Docetaxel in Castration-Resistant Prostate Cancer
Pilot Program Focuses on Improving Prostate Cancer Staging Data Entries
Prostate Cancer Foundation Announces Collaborative Research Grants Program
Niraparib Granted Breakthrough Therapy Designation in Metastatic Castration-Resistant Prostate Cancer
ESMO 2019: Does Olaparib Benefit Men With Advanced Castration-Resistant Prostate Cancer?
ASTRO 2019: SABR Versus Observation for Men With Oligometastatic Prostate Cancer
ESMO 2019: RADICALS-RT Trial Makes ‘Strong Case’ for Observation After Radical Prostatectomy
FDA Approves Apalutamide in Metastatic Castration-Sensitive Prostate Cancer
ASTRO 2019: PSA Level as Predictive Biomarker of Need for Long-Term Hormone Therapy
Quality Care 2019: BMD Testing in Men Initiating Hormone Therapy for Prostate Cancer
Quality Care 2019: End-of-Life Use of Hormonal Agents in Patients With Prostate Cancer
How Does HIV Infection Affect Survival in Patients With Prostate Cancer?
FDA Accepts New Drug Application for Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer
FDA Safety Update on Risk of Prostate Cancer and Treatment for Parkinson’s Disease
Is Body Fat Associated With Risk of Aggressive Prostate Cancer?
Epigenetic Regulator in Double-Negative Prostate Cancer
Darolutamide Approved by the FDA for Non-Metastatic Castration-Resistant Prostate Cancer
Potential Predictive Biomarkers for PSMA-Targeted Therapies in Prostate Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.